#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Transfusion and Haematology Today / 2021 - 3

Cryopreserved buffy-coat-derived platelets in platelet additive solution

Czech version

Authors: H. Lejdarová 1,2;  R. Pacasová 1;  N. Poloková 1;  S. Michlíčková 1;  L. Tesařová 3;  I. Koutná 3
Authors‘ workplace: Transfuzní a tkáňové oddělení, FN Brno 1;  LF MU, Brno 2;  Mezinárodní centrum klinického výzkumu, FN u sv. Anny, Brno 3
Published in: Transfuze Hematol. dnes,27, 2021, No. 3, p. 254-261.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2021254

Overview

The main disadvantage of fresh platelets is their short shelf life, usually 5 days, which can result in their restricted availability. Platelet cryopreservation extends shelf life up to 2 years when stored at a temperature of –80 °C. University Hospital Brno has implemented a method of platelet freezing at –80 °C in 5–6% dimethyl sulfoxide. Buffy-coat-derived leucodepleted blood group 0 fresh platelets are used for cryopreservation and reconstituted in platelet additive solution SSP+ after thawing. The authors present the results of a comparative study of cryopreserved and fresh buffy-coat-derived leucodepleted platelets going prior to clinical application. The following parameters were determined: platelet count and concentration, pH, volume, platelet loss, dimethyl sulfoxide content, plasma content, total protein content, ABO antibody titre and swirling. Viscoelastic properties were evaluated via rotational thromboelastometry and platelet microparticle numbers were measured by flow cytometry. Cryopreserved platelets met the required quality parameters and maintained an 83.6% pre-freeze platelet count. The very low plasma content resulted in a low total protein content (0.3 g/unit) and very low ABO antibody titre (0–2). Cryopreserved blood group O platelets reconstituted in SSP+ may thus be considered to be universal ABO products, even in clinical situations where washed platelets are required. Cryopreserved platelets showed faster clot initiation and the number of platelets microparticles increased 25 times compared to fresh platelets. These properties and the long shelf life predestine the use of cryopreserved platelets in urgent situations involving massive bleeding.

Keywords:

cryopreserved platelets – buffy-coat-derived platelets – dimethyl sulfoxide – platelet microparticles – platelet additive solution

Sources
  1. Schrezenmeier H, Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang. 2010; 99: 1–15.
  2. Lejdarová H. Trombocyty z aferézy a z plné krve – srovnání kvality a bezpečnosti. Transfuze Hematol Dnes. 2016; 22: 244–253.
  3. Cid J, Escolar G, Galan A, et al. In vitro evaluation of the hemostatic effectiveness of cryopreserved platelets. Transfusion. 2016; 56: 580–586.
  4. Johnson L, Reade MC, Hyland RA, Tan S, Marks DC. In vitro comparison of cryopreserved and liquid platelets: potential clinical implications. Transfusion. 2015; 55: 838–847.
  5. Valeri CR. Hemostatic effectiveness of liquid-preserved and previously frozen human platelets. N Engl J Med. 1974; 290: 353–358.
  6. Hornsey VS, McMillan L, Morrison A, Drummond O, MacGregor IR, Prowse CV. Freezing of buffy coat-derived, leukoreduced platelet concentrates in 6 percent dimethyl sulfoxide. Transfusion. 2008; 48: 2508–2514.
  7. Johnson L, Raynel S, Seghatchian J, Marks DC. Platelet microparticles in cryopreserved platelets: Potential mediators of haemostasis. Transfusion Apheresis Sci. 2015; 53: 146–152.
  8. Valeri CR, Ragno G, Khuri S. Freezing human platelets with 6 percent dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at –80 °C without postthaw processing. Transfusion. 2005; 45: 1890–1898.
  9. Bohoněk M. Kryokonzervace krve – historie, metody a současnost. Transfuze Hematol Dnes. 2013; 19: 44–50.
  10. Slichter SJ, Jones M, Ransom J, et al. Review of in vivo studies of dimethyl sulfoxide cryopreserved platelets. Transfusion Med Rev. 2014; 28: 212–225.
  11. Cohn CS, Dumont LJ, Lozano M, et al. Vox Sanguinis International Forum on platelet cryopreservation: Summary. Vox Sang. 2017; 112: 684–688.
  12. Johnson L, Reid S, Tan S, Vidovic D, Marks DC. PAS-G supports platelet reconstitution after cryopreservation in the absence of plasma. Transfusion. 2013; 53: 2268–2277.
  13. Johnson LN, Winter KM, Reid S, Hartkopf-Theis T, Marks DC. Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution. Cryobio­logy. 2011; 62: 100–106.
  14. Johnson L, Coorey CP, Marks DC. The hemostatic acitivity of cryopreserved platelets is mediated by phosphatidylserine-expressing platelets and platelet microparticles. Transfusion. 2014; 54: 1917–1926.
  15. Bohoněk M, Kutáč D, Landová L, et al. Kryokonzervované trombocyty v klinické praxi: srovnávací studie s nativními trombocyty. Transfuze Hematol Dnes. 2016; 22: 268–278.
  16. Ministerstvo zdravotnictví České republiky. Metodika systému zajištění přípravků a krevních derivátů při mimořádných událostech a krizových stavech. Vest Minist zdrav Čes repub. 2017; 2017: 3–11.
  17. European Directorate for the Quality of Medicines & Health Care. Guide to the preparation, use and quality assurance of blood components, 20th ed. Strasbourg, EDQM Publishers, 2020.
  18. Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019; 23: 98.
  19. Anani W, Triulzi D, Yazer MH, Qu L. Relative IgA-deficient recipients have an increased risk of severe allergic transfusion reactions. Vox Sang. 2014; 107: 389–392.
  20. Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K. ABO identical versus non identical platelet transfusion: a systematic review. Transfusion. 2009; 49: 2442–2453.
  21. Khuri S, Healey N, MacGregor H, et al. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thoracic Cardiovasc Surg. 1999; 117: 172–183.
  22. Doporučení Společnosti pro transfuzní lékařství ČLS JEP, č.STL2015_12 ze dne 01.09.2015 verze 1, dostupné z: https: //www.transfuznispolecnost.cz/doporucene-postupy/doporucene-postupy-pro-podani-transfuznich-pri­- pravku-230.
  23. Lelkens CCM, Koning JG, de Kort B, Floot IBG, Noorman F. Experiences with frozen blood products in the Netherlands military. Transfusion Apheresis Sci. 2006; 34: 289–298.
  24. Kelly K, Dumont LJ. Frozen platelets. Transfusion Apheresis Sci. 2019; 58: 23–29.
  25. Bohonek M, Kutac D, Landova L, et al. The use of cryopreserved platelets in the treatment of polytraumatic patients with massive bleeding. Transfusion. 2019; 59 (S2): 1474–1478.
Labels
Haematology Internal medicine Clinical oncology
New insights into the pathophysiology of Ph-negative myeloproliferative neoplasms
Changes in the immune system in untreated patients with chronic lymphocytic leukaemia – part 2: innate immune system
POEMS syndrome – a rare disease associated with monoclonal gammopathy and polyneuropathy: dia­gnosis and treatment
Laboratory dia­gnostics in immune-mediated thrombocytopenias
Ph negative myeloproliferative neoplasms in Czech haematological centres – MIND analysis
Multiple lymph node plasmacytosis with monoclonal gammopathy – plasma cell neoplasm or indolent B-lymphoma?
Primář MUDr. Jiří Horák, 11. 6. 1936 – 21. 6. 2021
Article was published in

Transfusion and Haematology Today

Issue 3
2021 Issue 3
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#